Navigation Links
DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference

. The day 90 median change from baseline was 6.0 and 5.0 NIHSS points in the DP-b99 and placebo groups, respectively; the day 90 median change from baseline in patients with entry NIHSS score of 10-16 was 8.0 and 5.0 points in the DP-b99 and placebo groups, respectively (p=0.03).

The trial enrolled patients within the first 9 hours following appearance of stroke symptoms. The data indicate that the effect of DP-b99 on recovery was uniform across the full 9h window, confirming the wide therapeutic window for DP-b99.

The favorable safety and tolerability profile of DP-b99 was confirmed and is in line with D-Pharm's previous clinical experience from the Phase I and IIa studies. There were no significant differences in the number or type of serious adverse events, mortality rate or death causes between the DP-b99 and placebo groups.

These results show that DP-b99 doubled the chances to recover from ischemic stroke, has at least a 9hr therapeutic window and is safe. D-Pharm is planning to commence a pivotal Phase III study of DP-b99 in 2008.

About D-Pharm Ltd.

D-Pharm (www.dpharm.com) is a biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich product pipeline from its drug targeting and discovery technologies, Regulated Activation of Prodrugs (D-RAPTM) and Membrane Active Chelators (MAC). The company expects to discuss the further development of DP-b99 with regulatory authorities in the coming months.

D-Pharm's pipeline includes DP-VPA, a new chemical entity that is a modified and targeted version of valproic acid for epilepsy, bipolar disorder treatment and migraine prophylaxis, currently in Phase II development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease.

    For further information please contact:


    Tami Horovitz, PhD.

    Tel: +972-8-9385100

 
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase IIb Trial Results Presented the European Stroke Conference
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/24/2014)... Pa. , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. ... J. Joseph Kim , President and CEO of Inovio Pharmaceuticals, ... management team to ring the Nasdaq Opening Bell tomorrow, Tuesday ... Inovio,s September 15 th listing on the Nasdaq Global ... ceremony, Dr. Kim said, "We are honored to ring the ...
(Date:11/22/2014)... 2014  New data demonstrates that flibanserin, a novel, ... of female sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), ... in premenopausal women when taken at bedtime. The data ... North America,s (SMSNA) 20th Annual Fall ... SMSNA accepted this study as a late ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3
... The National,Comprehensive Cancer Network (NCCN) announces updates to ... Cancer,and Gastric Cancer. The NCCN Guidelines are updated ... recognized and,applied as the standard of care in ... and the academic practice settings., In response to ...
... of the Most Challenging Patient Populations,Studied of Any ... PARK, Calif., May 22, 2007,/PRNewswire-FirstCall/ -- XTENT, Inc. ... clinical trial, which assessed,the safety and efficacy of ... for the treatment of long and,multiple lesions in ...
Cached Medicine Technology:NCCN Updates Esophageal and Gastric Cancer Guidelines 2NCCN Updates Esophageal and Gastric Cancer Guidelines 3XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 2XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 3XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 4
(Date:11/24/2014)... 24, 2014 Gersowitz Libo & Korek, P.C., ... received national Tier recognition in the 2015 Edition of U.S. ... ranking signals a unique combination of quality law practice and ... receive this honor and especially grateful to our clients whose ... and ranking possible,” said Jeff S. Korek, senior partner at ...
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled ... They are now offered at deeply discounted prices, up ... now to Dec. 15. The main purpose of the promotion ... high quality items are ideal options for ladies who are ... money. All its new mint cocktail dresses are very beautiful; ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
(Date:11/23/2014)... 2014 Locks-Magnetic.com, a notable magnetic locks ... all the new products are available at low rates ... is proud of the new emergency doors. The emergency ... customers can choose from several colors. All of the ... emergency door release is not as easy as many ...
(Date:11/23/2014)... More than two dozen new claims ... litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well ... reports. , A Case List updated on November ... Type 2 diabetes medications referred to as incretin mimetics ... Southern District of California, where a federal proceeding continues ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... after women have separated from an abusive partner, the violence still ... at the University of British Columbia. Led by UBC Nursing ... of Canadian Public Policy is the first in ... used by women who leave a violent partner. Overall, ...
... and Reinvestment Act award from the Agency for Healthcare ... Indiana Network for Patient Care (INPC), the nation,s largest ... simultaneously supports a groundbreaking comparative effectiveness research study using ... harms of three drugs commonly used to treat Alzheimer,s ...
... A pioneering international collaboration forged by Fred Hutchinson ... with the Uganda Cancer Institute in Kampala, Uganda, ... a state-of-the-art cancer training and outpatient treatment facility ... comprehensive cancer center jointly constructed by U.S. and ...
... by University of Cincinnati (UC) faculty members shows that ... clinical experience helps internal medicine residents improve their scores ... findings, published in the advance online edition of the ... print in November, validate the benefit of this and ...
... of 606 Canadian physicians were disciplined by their provincial ... St. Michael,s Hospital found. The majority of disciplined ... practicing medicine for a long time (an average of ... according to Dr. Chaim Bell. The most frequent ...
... wild, poisonous mushroom growing in a Southwest China forest appears ... report. , The compound, verticillin A, sensitizes cancer cells to ... said Dr. Kebin Liu, cancer immunologist at the Georgia Health ... in the journal Cancer Research . , The compound ...
Cached Medicine News:Health News:Annual cost of violence pegged at $6.9 billion after women leave abusive partners, UBC research 2Health News:$8.4 million grant supports health information exchange and research on Alzheimer's drugs 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 3Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 4Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 5Health News:New testing program improves scores, knowledge retention for third-year internal medicine residents 2Health News:New testing program improves scores, knowledge retention for third-year internal medicine residents 3Health News:Researchers track number of doctors disciplined and why 2Health News:Mushroom compound appears to improve effectiveness of cancer drugs 2
ISYSTEM-ABDv2™A/B Scan unit. True Geometry With Stepped Zoom, Pan, Freeze Frame, Post Image Processing....
... The CineScan A/B represent a true ... analog image with technology and diagnostic capability ... in the vitreous. Adjust the gain up ... would be invisible at a standard 90db ...
PremierEdge Stab Knives - 30....
PremierEdge™ Stab Knives - 15°....
Medicine Products: